Travere Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August:

2024 Wedbush PacGrow Healthcare Conference
Tuesday, August 13, 2024, at 2:30 p.m. ET

Canaccord Genuity 44th Annual Growth Conference
Wednesday, August 14, 2024, at 12:30 p.m. ET

A live webcast of the Canaccord Genuity 44th Annual Growth Conference presentation will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Contact:

Investors:
888-969-7879                                        
IR@travere.com
Media:
888-969-7879                                        
mediarelations@travere.com


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  199.31
-4.77 (-2.34%)
AAPL  264.71
-10.79 (-3.91%)
AMD  207.83
-5.75 (-2.69%)
BAC  52.16
-1.70 (-3.15%)
GOOG  314.42
+3.09 (0.99%)
META  653.03
-15.66 (-2.34%)
MSFT  401.55
-2.82 (-0.70%)
NVDA  189.54
-0.51 (-0.27%)
ORCL  155.78
-1.38 (-0.88%)
TSLA  419.17
-9.10 (-2.12%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.